+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Gastroparesis Drugs Market by Product Type (Branded, Generics), Drug Class (Dopamine Antagonists, Motilin Receptor Agonists, Serotonin Receptor Agonists), Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Gastroparesis Drugs Market by Product Type (Branded, Generics), Drug Class (Dopamine Antagonists, Motilin Receptor Agonists, Serotonin Receptor Agonists), Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Sale

Gastroparesis Drugs Market by Product Type (Branded, Generics), Drug Class (Dopamine Antagonists, Motilin Receptor Agonists, Serotonin Receptor Agonists), Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 189 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5924669
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The gastroparesis drugs market is experiencing steady evolution as new clinical innovations, shifting regulatory frameworks, and global economic factors drive changes in therapeutic strategies and access. For senior decision-makers, this dynamic environment presents both opportunities and operational challenges in aligning portfolios, shaping partnerships, and navigating global care pathways.

Market Snapshot: Gastroparesis Drugs Market Growth and Competitive Dynamics

The Gastroparesis Drugs Market grew from USD 4.54 billion in 2024 to USD 4.87 billion in 2025. It is expected to continue growing at a CAGR of 7.11%, reaching USD 6.85 billion by 2030. Market expansion is propelled by advanced therapeutics, evolving care protocols, and adaptive regulatory environments. This sector’s competitive landscape is marked by established pharmaceutical players, emerging biotech entrants, and an increasing rate of strategic partnerships targeting innovative modalities.

Scope & Segmentation: Comprehensive Breakdown of Gastroparesis Therapeutics

  • Product Types: Includes both branded and generic drugs, balancing proprietary features against wider reimbursement access.
  • Drug Classes: Incorporates dopamine antagonists (cisapride, domperidone, metoclopramide), motilin receptor agonists (azithromycin, erythromycin), and serotonin receptor agonists (granisetron, ondansetron).
  • Routes of Administration: Covers injectable formulations for acute settings, oral therapies for chronic management, and transdermal innovations for patients with severe symptoms.
  • Distribution Channels: Spans hospital pharmacies, online pharmacies, and retail pharmacy outlets, each shaping drug accessibility and patient experiences.
  • End Users: Targets clinics, home care environments, and hospitals, where tailored services and supply chain solutions are critical.
  • Regional Markets: Segmented across Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (key EU and GCC countries, sub-Saharan Africa), and Asia-Pacific (China, India, Japan, Australia, Southeast Asia, and more).
  • Key Companies: Profiles major industry participants, including Teva Pharmaceutical Industries Ltd., Viatris Inc., Sandoz International GmbH, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Johnson & Johnson, AbbVie Inc., Ironwood Pharmaceuticals, Inc., Motus GI Holdings, Inc., and Pfizer Inc.

Key Takeaways: Strategic Insights for Gastroparesis Drugs Decision Makers

  • Growing emphasis on novel prokinetic compounds and combination therapies is transforming clinical management and supporting pipeline diversification.
  • Stakeholder collaboration is expanding, reflected in co-marketing agreements, research alliances, and partnerships focused on digital adherence and remote monitoring innovations.
  • Regional disparities in healthcare infrastructure, reimbursement protocols, and regulatory policies are actively shaping market access, prompting tailored go-to-market and alliance strategies.
  • Generics remain pivotal in driving volume growth, while branded drugs lead in differentiation, supported by patient access programs and proprietary delivery approaches.
  • Distribution channel diversification, including the rise of online pharmacies and direct-to-patient models, is enhancing convenience and adherence in chronic gastroparesis care.
  • Real-world data initiatives and adaptive clinical trial designs are accelerating approval timelines and informing outcome-based payment frameworks globally.

Tariff Impact: Navigating the 2025 US Tariff Changes on Gastroparesis Drug Markets

The imposition of revised US tariff structures in 2025 is increasing production costs for gastroparesis drugs by raising duties on active pharmaceutical ingredients. Pharmaceutical companies are accelerating regional manufacturing investments, diversifying raw material sourcing, and optimizing formulation processes to maintain cost-efficiency and protect margins. Innovations in contracting, such as risk-sharing agreements aligned with clinical outcomes, are gaining traction as industry participants adapt to shifting trade and pricing dynamics. Enhanced focus on domestic logistics and direct-to-patient distribution is helping to buffer supply chain risks linked to tariff policies.

Methodology & Data Sources: Reliable, Comprehensive Gastroparesis Drug Market Research

This research utilizes a dual-method approach, combining qualitative interviews with industry experts—including gastroenterologists, pharmacologists, and reimbursement specialists—with rigorous analysis of peer-reviewed publications, regulatory filings, and company disclosures. Scenario modeling and independent review cycles ensure trend validation and accurate, actionable strategic recommendations.

Why This Report Matters: Actionable Guidance for B2B Strategic Planning

  • Enables evidence-based portfolio and alliance planning by highlighting shifting therapeutic trends, emerging opportunities, and the competitive landscape.
  • Supports agile operational decision-making as supply chain, pricing, and policy factors evolve in key regions and segments.
  • Informs investment strategies with robust data on pipeline dynamics, reimbursement models, and regulatory developments shaping the future of gastroparesis care.

Conclusion

The Gastroparesis Drugs Market is reshaping itself through clinical innovation, adaptive strategy, and renewed collaboration. Stakeholders who align R&D, operations, and market access will drive effective solutions and sustainable sector growth.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Increasing adoption of novel ghrelin receptor agonists demonstrating improved gastric motility in refractory gastroparesis patients
5.2. Emerging use of noninvasive gastric electrical stimulation devices for outpatient management of diabetic gastroparesis symptoms
5.3. Advancements in formulation of sustained release metoclopramide to minimize central nervous system side effects in long term therapy
5.4. Rising investment in oral small molecule prokinetics targeting multiple receptor pathways to overcome current therapeutic limitations
5.5. Integration of real world evidence from patient registries to support reimbursement of high cost gastroparesis biologic therapies
5.6. Expansion of pipeline trials assessing combination therapies of serotonergic and motilin analogs for synergistic prokinetic effects
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Gastroparesis Drugs Market, by Product Type
8.1. Introduction
8.2. Branded
8.3. Generics
9. Gastroparesis Drugs Market, by Drug Class
9.1. Introduction
9.2. Dopamine Antagonists
9.2.1. Cisapride
9.2.2. Domperidone
9.2.3. Metoclopramide
9.3. Motilin Receptor Agonists
9.3.1. Azithromycin
9.3.2. Erythromycin
9.4. Serotonin Receptor Agonists
9.4.1. Granisetron
9.4.2. Ondansetron
10. Gastroparesis Drugs Market, by Route Of Administration
10.1. Introduction
10.2. Injectable
10.3. Oral
10.4. Transdermal
11. Gastroparesis Drugs Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacy
11.3. Online Pharmacy
11.4. Retail Pharmacy
12. Gastroparesis Drugs Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Home Care Settings
12.4. Hospitals
13. Americas Gastroparesis Drugs Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Gastroparesis Drugs Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Gastroparesis Drugs Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Teva Pharmaceutical Industries Ltd.
16.3.2. Viatris Inc.
16.3.3. Sandoz International GmbH
16.3.4. Sun Pharmaceutical Industries Ltd.
16.3.5. Dr. Reddy's Laboratories Ltd.
16.3.6. Johnson & Johnson
16.3.7. AbbVie Inc.
16.3.8. Ironwood Pharmaceuticals, Inc.
16.3.9. Motus GI Holdings, Inc.
16.3.10. Pfizer Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. GASTROPARESIS DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GASTROPARESIS DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. GASTROPARESIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. GASTROPARESIS DRUGS MARKET: RESEARCHAI
FIGURE 26. GASTROPARESIS DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 27. GASTROPARESIS DRUGS MARKET: RESEARCHCONTACTS
FIGURE 28. GASTROPARESIS DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. GASTROPARESIS DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GENERICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GENERICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY CISAPRIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY CISAPRIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOMPERIDONE, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOMPERIDONE, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY METOCLOPRAMIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY METOCLOPRAMIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY AZITHROMYCIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY AZITHROMYCIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ERYTHROMYCIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ERYTHROMYCIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GRANISETRON, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY GRANISETRON, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONDANSETRON, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONDANSETRON, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL GASTROPARESIS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES GASTROPARESIS DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 103. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 104. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 105. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 106. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 107. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 108. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 109. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
TABLE 110. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2025-2030 (USD MILLION)
TABLE 111. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
TABLE 112. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2025-2030 (USD MILLION)
TABLE 113. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 114. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 115. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 116. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 117. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 118. CANADA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 119. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 120. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 121. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 122. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 123. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 124. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 125. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
TABLE 126. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2025-2030 (USD MILLION)
TABLE 127. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
TABLE 128. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2025-2030 (USD MILLION)
TABLE 129. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 130. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 131. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 132. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 133. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 134. MEXICO GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 149. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 150. BRAZIL GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 163. ARGENTINA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 164. ARGENTINA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 165. ARGENTINA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 166. ARGENTINA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 186. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 188. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
TABLE 192. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2025-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
TABLE 194. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2025-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 196. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 198. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 200. UNITED KINGDOM GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 201. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 202. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 203. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 204. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 205. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 206. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 207. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
TABLE 208. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2025-2030 (USD MILLION)
TABLE 209. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
TABLE 210. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2025-2030 (USD MILLION)
TABLE 211. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 212. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 213. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 214. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 215. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 216. GERMANY GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 217. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 218. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 219. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 220. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 221. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 222. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 223. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
TABLE 224. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2025-2030 (USD MILLION)
TABLE 225. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
TABLE 226. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2025-2030 (USD MILLION)
TABLE 227. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 228. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 229. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 230. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 231. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 232. FRANCE GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 233. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 234. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 235. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 236. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 237. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 238. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 239. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
TABLE 240. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2025-2030 (USD MILLION)
TABLE 241. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
TABLE 242. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2025-2030 (USD MILLION)
TABLE 243. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 244. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 245. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 246. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 247. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 248. RUSSIA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 249. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 250. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 251. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 252. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 253. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 254. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 255. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
TABLE 256. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2025-2030 (USD MILLION)
TABLE 257. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
TABLE 258. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2025-2030 (USD MILLION)
TABLE 259. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 260. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 261. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 262. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 263. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 264. ITALY GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 265. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 266. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 267. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 268. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 269. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 270. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 271. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
TABLE 272. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2025-2030 (USD MILLION)
TABLE 273. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
TABLE 274. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2025-2030 (USD MILLION)
TABLE 275. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 276. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 277. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 278. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 279. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 280. SPAIN GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
TABLE 288. UNITED ARAB EMIRATES GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2025-2030 (USD MILLION)
TABLE 289. UNITED ARAB EMIRATES GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
TABLE 290. UNITED ARAB EMIRATES GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2025-2030 (USD MILLION)
TABLE 291. UNITED ARAB EMIRATES GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 292. UNITED ARAB EMIRATES GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 293. UNITED ARAB EMIRATES GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 294. UNITED ARAB EMIRATES GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 295. UNITED ARAB EMIRATES GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 296. UNITED ARAB EMIRATES GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 297. SAUDI ARABIA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 298. SAUDI ARABIA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 299. SAUDI ARABIA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 300. SAUDI ARABIA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 301. SAUDI ARABIA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 302. SAUDI ARABIA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 303. SAUDI ARABIA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
TABLE 304. SAUDI ARABIA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2025-2030 (USD MILLION)
TABLE 305. SAUDI ARABIA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
TABLE 306. SAUDI ARABIA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2025-2030 (USD MILLION)
TABLE 307. SAUDI ARABIA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 308. SAUDI ARABIA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 309. SAUDI ARABIA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 310. SAUDI ARABIA GASTROPARESIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 311. SAUDI ARABIA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 312. SAUDI ARABIA GASTROPARESIS DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 313. SOUTH AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 314. SOUTH AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 315. SOUTH AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 316. SOUTH AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 317. SOUTH AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 318. SOUTH AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 319. SOUTH AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
TABLE 320. SOUTH AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY MOTILIN RECEPTOR AGONISTS, 2025-2030 (USD MILLION)
TABLE 321. SOUTH AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2018-2024 (USD MILLION)
TABLE 322. SOUTH AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY SEROTONIN RECEPTOR AGONISTS, 2025-2030 (USD MILLION)
TABLE 323. SOUTH AFRICA GASTROPARESIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 324. SOUTH AFRICA GASTROPARESIS DRUGS MARKET SIZE,

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Gastroparesis Drugs market report include:
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Johnson & Johnson
  • AbbVie Inc.
  • Ironwood Pharmaceuticals, Inc.
  • Motus GI Holdings, Inc.
  • Pfizer Inc.

Table Information

Report AttributeDetails
No. of Pages189
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 4.87 Billion
Forecasted Market Value ( USD ) by 2030 $ 6.85 Billion
Compound Annual Growth Rate7.1%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Gastroparesis Drugs - Global Strategic Business Report - Product Image

Gastroparesis Drugs - Global Strategic Business Report

  • Report
  • 197 Pages
  • Global
From
Diabetic Gastroparesis Drug Pipeline Analysis Report 2025 - Product Image

Diabetic Gastroparesis Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • 200 Pages
  • Global
From
Gastroparesis Drugs Market Report 2025 - Product Image

Gastroparesis Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Gastroparesis Drugs Market Report by Disease Type, Drug Class, Distribution Channel, and Region 2024-2032 - Product Image

Gastroparesis Drugs Market Report by Disease Type, Drug Class, Distribution Channel, and Region 2024-2032

  • Report
  • 143 Pages
  • Global
From
Gastroparesis Drugs Market 2025-2029 - Product Image

Gastroparesis Drugs Market 2025-2029

  • Report
  • 198 Pages
  • Global
From

About the Gastroparesis Drug Market

Gastroparesis Drug is a type of drug used to treat gastroparesis, a condition in which the stomach muscles are weakened and unable to properly move food through the digestive system. These drugs are used to reduce symptoms such as nausea, vomiting, bloating, and abdominal pain. Commonly prescribed drugs for gastroparesis include metoclopramide, domperidone, and erythromycin. Other drugs, such as prokinetics, may also be used to help improve gastric emptying. Gastroparesis Drug is a part of the larger Gastrointestinal Drugs market, which includes drugs used to treat a variety of gastrointestinal conditions. These drugs are used to reduce symptoms, improve digestion, and prevent further complications. Commonly prescribed drugs in this market include antacids, proton pump inhibitors, and laxatives. Some companies in the Gastroparesis Drug market include Novartis, GlaxoSmithKline, Pfizer, and Takeda. Other companies, such as Allergan, Merck, and AstraZeneca, also produce drugs for the treatment of gastroparesis. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.